Adial Pharmaceuticals, Inc. (ADIL)
- Previous Close
0.6925 - Open
0.6777 - Bid 0.6215 x 100
- Ask 0.6828 x 100
- Day's Range
0.6347 - 0.6900 - 52 Week Range
0.5800 - 3.0000 - Volume
254,945 - Avg. Volume
1,309,429 - Market Cap (intraday)
4.284M - Beta (5Y Monthly) 1.22
- PE Ratio (TTM)
-- - EPS (TTM)
-2.7200 - Earnings Date May 12, 2025 - May 16, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
6.50
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Glen Allen, Virginia.
www.adial.comRecent News: ADIL
View MorePerformance Overview: ADIL
Trailing total returns as of 5/7/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ADIL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ADIL
View MoreValuation Measures
Market Cap
4.28M
Enterprise Value
2.17M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.05
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-105.88%
Return on Equity (ttm)
-323.80%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-13.2M
Diluted EPS (ttm)
-2.7200
Balance Sheet and Cash Flow
Total Cash (mrq)
3.75M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-3.99M